Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 10/20 | 0.80 |
| ▸ | GSK3B | P49841 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 8/20 | 0.51 |
| ▸ | RAB9A | P51151 | 8/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30387563 | 1.00 | WNT3A (0.80) | WNT3AGSK3BNPC1RAB9APKM | |
| SCHEMBL30388081 | 0.90 | WNT3A (0.71) | WNT3AGSK3BNPC1RAB9APKM | |
| SCHEMBL20604328 | 0.90 | WNT3A (0.71) | WNT3AGSK3BNPC1RAB9APKM | |
| SCHEMBL20604124 | 0.89 | WNT3A (0.71) | WNT3AGSK3BNPC1RAB9APKM | |
| SCHEMBL30387473 | 0.89 | WNT3A (0.71) | WNT3AGSK3BNPC1RAB9APKM | |
| SCHEMBL20604119 | 0.89 | WNT3A (1.00) | WNT3AGSK3BNPC1RAB9AMTOR | |
| SCHEMBL20604134 | 0.89 | WNT3A (0.77) | WNT3AGSK3BNPC1RAB9ACASP3 | |
| SCHEMBL20604107 | 0.89 | WNT3A (0.77) | WNT3AGSK3BNPC1RAB9ACASP3 | |
| SCHEMBL20604128 | 0.89 | WNT3A (0.77) | WNT3AGSK3BNPC1RAB9ACASP3 | |
| SCHEMBL30387730 | 0.89 | WNT3A (0.77) | WNT3AGSK3BNPC1RAB9ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | claimed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | claimed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | claimed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | claimed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | claimed |
| EP-3423452-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2019-01-09 | — | — | EP | claimed |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3423452-B1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV MARYLAND (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | WNT3A 3/4885GSK3B 8/4885NPC1 301/4885 |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | WNT3A 3/4885GSK3B 8/4885NPC1 301/4885 |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | WNT3A 3/4885GSK3B 8/4885NPC1 301/4885 |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | WNT1, CTNNB1, WNT3A | WNT3A 3/4885GSK3B 8/4885NPC1 301/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | WNT3A 3/4885GSK3B 8/4885NPC1 301/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | WNT3A 5/4885GSK3B 11/4885NPC1 598/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | WNT3A 3/4885GSK3B 8/4885NPC1 301/4885 |
| US-10723715-B2 | — | CTNNB1, WNT1, CTNNBL1 | WNT3A 4/4885GSK3B 9/4885NPC1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.